Abstract
ObjectiveTo explore the clinical and biological prognostic factors for advanced ovarian cancer patients receiving first-line treatment with carboplatin, paclitaxel, and bevacizumab.MethodsA multicenter, phase IV, single arm trial was performed. Patients...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have